

ASX ANNOUNCEMENT
ASX:RSH

28 December 2022

Respiri Announces Security Purchase Plan

Respiri Limited (ASX:RSH) ("Respiri" or the "Company"), an eHealth SaaS Company supporting respiratory health management, is pleased to announce an underwritten Security Purchase Plan ("**SPP**") to raise funds up to \$1.5 million ("**SPP Offer**").

Highlights

- The SPP is to raise funds up to \$1.5 million, which may be scaled back or increased by the Company at its absolute discretion.
- The SPP is underwritten for up to \$1.5 million.
- The Issue price will be:
 - i. \$0.05 per fully paid ordinary share, provided that the market price of RSH's shares at some stage during the 30 days before the date of issue is \$0.05; and
 - ii. in the event that the market price of RSH's shares during the 30 days before the date of issue does not reach \$0.05, then the issue price will be the highest market price reached by RSH shares during the 30 days before the date of issue.

However, the Company notes that in the event that the market price of RSH's shares during the 30 days before the date of issue does not reach \$0.05, the Board may (at its absolute discretion) elect to reject applications received under the SPP pursuant to the allocation policy.

Security Purchase Plan

Today, Respiri announces a Security Purchase Plan (SPP) to raise \$1.5 million in funds (before costs). The Company may, at its absolute discretion, increase the SPP Offer, subject to shareholder demand and accept oversubscriptions under the SPP.

The SPP Offer to eligible shareholders provides the opportunity to purchase up to \$30,000 of new Respiri shares under the SPP offer at \$0.05 per share ("**New Shares**"). The SPP is limited to shareholders with a registered address in Australia and New Zealand who are shareholders as at the record date of Tuesday, 27 December 2022. It is anticipated that the SPP offer will be open from Friday, 30 December 2022 to Friday, 27 January 2023.

The SPP offer is underwritten by independent sophisticated and professional investors for up to \$1.5 million ("**Underwriters**").

The Company reserves the right to scale back applications at its discretion in the event applications in excess of that amount are received.

The SPP is part of a capital raising undertaken to support the Company's expansion into the US and enable the Company to execute on its commercialisation strategy.

The indicative timetable for the SPP is as follows.

Event	Date
Record Date for SPP Offer	Tuesday 27 December 2022
Announcement of SPP	Wednesday 28 December 2022
Cleaning notice issued	Thursday 29 December 2022
Dispatch of Offer Document to Eligible Shareholders and Opening Date	Friday 30 December 2022
Closing Date	Friday 27 January 2023
Announcement of results of SPP Offer	Wednesday 1 February 2023
Allotment Date for New Shares	Tuesday 7 February 2023
New Shares commence trading on ASX	Thursday 9 February 2023

**The above timetable is only indicative, and the Company reserves the right to vary any of the above dates other than the Record Date.*

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

™ wheezo is a trademark of Respiri Limited.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such

products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiro, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiro cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiro only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiro will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.